About Shanghai Yusong Biotechnology
Shanghai United Cell Biotechnology, established in 1995 in the Shanghai Free Trade Zone, operates a biopharmaceutical facility spanning 20,000 square meters at 1150 Gui Qiao Lu. The company focuses on:
- Gene-engineered vaccines and therapeutic products
- Lyophilized powder injections and cartridge water injections
- Research in endocrinology, orthopedics and ophthalmology
- GMP-standard manufacturing facilities
With USD 61.15 million in registered capital and expansion to Zhuhai, the company maintains robust R&D programs for growth hormone, osteoporosis and ophthalmic treatments.
Frequently asked questions
Shanghai United Cell Biotechnology manufactures biological products in these categories:
- Therapeutic Injections
- Teriparatide injection
- Human growth hormone injection
- Freeze-dried powder injections
- Cartridge vial injections
- Vaccines
- Recombinant B subunit cholera vaccine
- Whole cell cholera vaccine (enteric-coated capsules)
- Other Formulations
- Capsule products
- Granule products
Annual production capacity includes 15 million freeze-dried injections, 13 million cartridge vial injections, 9 million capsules, and 5.6 million bags of granules.
The company maintains these R&D and manufacturing standards:
| Category | Details |
|---|---|
| Research Platforms |
|
| Therapeutic Areas |
|
| Quality Systems |
|
The company operates from the following facilities:
- Manufacturing Complex
- 20,000 square meter facility footprint
- 24,000 square meter total building area
- Located in Shanghai Free Trade Zone
- Production Workshops
- Genetic engineering bulk production
- Cholera vibrio bulk production
- Injection production units
- Capsule manufacturing area
- Granule processing section
Primary Location:
Shanghai United Cell BiotechnologyJinqiao Biotechnology Industrial Park
Shanghai Free Trade Zone
Shanghai, China
More details about Shanghai Yusong Biotechnology
A leading biotechnology company in Shanghai
Shanghai United Cell Biotechnology, established in 1995, has grown into a prominent biotechnology enterprise within China’s pharmaceutical sector. Operating from the Shanghai Free Trade Zone’s Jinqiao Biotechnology Industrial Park, the company combines advanced research capabilities with state-of-the-art manufacturing facilities.
Advanced facilities and production capabilities
The company’s facility encompasses 44,000 square meters of total space, housing both cosmetic lab operations and pharmaceutical manufacturing units. The production infrastructure includes specialized areas for genetic engineering, vaccine development, and various pharmaceutical formulations.
Manufacturing capacity
- 15 million freeze-dried injections annually
- 13 million cartridge vial injections
- 9 million capsules
- 5.6 million granule bags
Research and development focus
With over 10% of sales revenue directed towards R&D, Shanghai United Cell Biotechnology maintains active research platforms in multiple therapeutic areas. The company’s work spans across:
- Endocrinology
- Orthopedics
- Ophthalmology
- Anti-infection treatments
Product portfolio and expertise
Operating under strict GMP compliance, the company produces several key products including teriparatide injections, cholera vaccines, and human growth hormone preparations. The manufacturing process utilizes both prokaryotic and eukaryotic expression systems.
Strategic location and market access
Located at 1150 Gui Qiao Lu in Shanghai’s Free Trade Zone, the facility benefits from the region’s established biotechnology infrastructure and proximity to major transportation networks. This position supports efficient distribution across Asian markets while maintaining compliance with international standards.
Company gallery
